{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T17:55:10Z","timestamp":1785866110347,"version":"3.56.0"},"reference-count":53,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,1,5]],"date-time":"2026-01-05T00:00:00Z","timestamp":1767571200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100012353","name":"German Cancer Consortium","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100012353","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003495","name":"Hessisches Ministerium f\u00fcr Wissenschaft und Kunst","doi-asserted-by":"publisher","award":["III L 5 - 519 \/03\/03.001 - (0015)"],"award-info":[{"award-number":["III L 5 - 519 \/03\/03.001 - (0015)"]}],"id":[{"id":"10.13039\/501100003495","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100018992","name":"Fonds der Chemischen Industrie","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100018992","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001659","name":"German Research Foundation","doi-asserted-by":"publisher","award":["ME 3621 \/2-1"],"award-info":[{"award-number":["ME 3621 \/2-1"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001659","name":"German Research Foundation","doi-asserted-by":"publisher","award":["INST 35 \/1597-1 FUGG"],"award-info":[{"award-number":["INST 35 \/1597-1 FUGG"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jhep-reports.eu","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["JHEP Reports"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1016\/j.jhepr.2026.101731","type":"journal-article","created":{"date-parts":[[2026,1,9]],"date-time":"2026-01-09T00:32:18Z","timestamp":1767918738000},"page":"101731","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Co-administered internalizing RGD peptide boosts anti-PD-L1 therapy in hepatocellular carcinoma"],"prefix":"10.1016","volume":"8","author":[{"given":"Jan Henrik","family":"Klug","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-1553-7687","authenticated-orcid":false,"given":"Blerina","family":"Aliraj","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucia","family":"Alcober-Boquet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4887-1492","authenticated-orcid":false,"given":"Dominic","family":"Denk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lena","family":"Germann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0211-352X","authenticated-orcid":false,"given":"Nadja M.","family":"Meindl-Beinker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8918-2266","authenticated-orcid":false,"given":"Carolina","family":"De La Torre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oliver","family":"Waidmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabian","family":"Finkelmeier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan","family":"Zeuzem","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bernhard","family":"Br\u00fcne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas J.","family":"Vogl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7529-1952","authenticated-orcid":false,"given":"Andreas","family":"Weigert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0131-3669","authenticated-orcid":false,"given":"Albrecht","family":"Piiper","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jhepr.2026.101731_bib1","article-title":"Immunotherapy for hepatocellular carcinoma","volume":"6","author":"Childs","year":"2024","journal-title":"JHEP Rep"},{"key":"10.1016\/j.jhepr.2026.101731_bib2","doi-asserted-by":"crossref","DOI":"10.1056\/EVIDoa2100070","article-title":"Tremelimumab plus durvalumab in unresectable hepatocellular carcinoma","volume":"1","author":"Abou-Alfa","year":"2022","journal-title":"NEJM Evid"},{"key":"10.1016\/j.jhepr.2026.101731_bib3","doi-asserted-by":"crossref","first-page":"1894","DOI":"10.1056\/NEJMoa1915745","article-title":"Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma","volume":"382","author":"Finn","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jhepr.2026.101731_bib4","doi-asserted-by":"crossref","first-page":"e1216","DOI":"10.1002\/onco.13776","article-title":"Immune-checkpoint inhibitors for advanced hepatocellular carcinoma: a synopsis of response rates","volume":"26","author":"Shek","year":"2021","journal-title":"Oncologist"},{"key":"10.1016\/j.jhepr.2026.101731_bib5","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2020.601240","article-title":"Immune checkpoint inhibitors in the treatment of HCC","volume":"10","author":"Donisi","year":"2021","journal-title":"Front Oncol"},{"key":"10.1016\/j.jhepr.2026.101731_bib6","article-title":"Mechanisms of tumor resistance to immune checkpoint blockade and combination strategies to overcome resistance","volume":"13","author":"Zhou","year":"2022","journal-title":"Front Immunol"},{"key":"10.1016\/j.jhepr.2026.101731_bib7","doi-asserted-by":"crossref","first-page":"1851","DOI":"10.1016\/S0140-6736(25)00403-9","article-title":"Nivolumab plus ipilimumab versus lenvatinib or sorafenib as first-line treatment for unresectable hepatocellular carcinoma (CheckMate 9DW): an open-label, randomised, phase 3 trial","volume":"405","author":"Yau","year":"2025","journal-title":"Lancet"},{"key":"10.1016\/j.jhepr.2026.101731_bib8","first-page":"209","article-title":"Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.jhepr.2026.101731_bib9","doi-asserted-by":"crossref","first-page":"1830","DOI":"10.1200\/JCO.23.02745","article-title":"Systemic therapy for advanced hepatocellular carcinoma: ASCO Guideline Update","volume":"42","author":"Gordan","year":"2024","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jhepr.2026.101731_bib10","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1007\/s13346-023-01405-9","article-title":"Drug delivery methods for cancer immunotherapy","volume":"14","author":"P\u00e9rez-Herrero","year":"2024","journal-title":"Drug Deliv Transl Res"},{"key":"10.1016\/j.jhepr.2026.101731_bib11","first-page":"115S","article-title":"Perspectives on cancer therapy with radiolabeled monoclonal antibodies","volume":"46","author":"Sharkey","year":"2005","journal-title":"J Nucl Med"},{"key":"10.1016\/j.jhepr.2026.101731_bib12","doi-asserted-by":"crossref","first-page":"1421","DOI":"10.1016\/j.addr.2008.04.012","article-title":"Antibody tumor penetration: transport opposed by systemic and antigen-mediated clearance","volume":"60","author":"Thurber","year":"2008","journal-title":"Adv Drug Deliv Rev"},{"key":"10.1016\/j.jhepr.2026.101731_bib13","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2019-000400","article-title":"Poor outcome with anti-programmed death-ligand 1 (PD-L1) antibody due to poor pharmacokinetic properties in PD-1\/PD-L1 blockade-sensitive mouse models","volume":"8","author":"Kurino","year":"2020","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.jhepr.2026.101731_bib14","doi-asserted-by":"crossref","first-page":"16157","DOI":"10.1073\/pnas.0908201106","article-title":"C-end rule peptides mediate neuropilin-1-dependent cell, vascular, and tissue penetration","volume":"106","author":"Teesalu","year":"2009","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.jhepr.2026.101731_bib15","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1126\/science.1183057","article-title":"Coadministration of a tumor-penetrating peptide enhances the efficacy of cancer drugs","volume":"328","author":"Sugahara","year":"2010","journal-title":"Science"},{"key":"10.1016\/j.jhepr.2026.101731_bib16","doi-asserted-by":"crossref","first-page":"3147","DOI":"10.1158\/0008-5472.CAN-15-0395","article-title":"Improving drug penetrability with iRGD leverages the therapeutic response to sorafenib and doxorubicin in hepatocellular carcinoma","volume":"75","author":"Schmithals","year":"2015","journal-title":"Cancer Res"},{"key":"10.1016\/j.jhepr.2026.101731_bib17","doi-asserted-by":"crossref","first-page":"3241","DOI":"10.3892\/ol.2016.5081","article-title":"Tumor-penetration and antitumor efficacy of cetuximab are enhanced by co-administered iRGD in a murine model of human NSCLC","volume":"12","author":"Zhang","year":"2016","journal-title":"Oncol Lett"},{"key":"10.1016\/j.jhepr.2026.101731_bib18","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.addr.2016.03.008","article-title":"Tumor penetrating peptides for improved drug delivery","volume":"110\u2013111","author":"Ruoslahti","year":"2017","journal-title":"Adv Drug Deliv Rev"},{"key":"10.1016\/j.jhepr.2026.101731_bib19","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1016\/j.ccr.2009.10.013","article-title":"Tissue-penetrating delivery of compounds and nanoparticles into tumors","volume":"16","author":"Sugahara","year":"2009","journal-title":"Cancer Cell"},{"key":"10.1016\/j.jhepr.2026.101731_bib20","doi-asserted-by":"crossref","first-page":"1257","DOI":"10.1161\/01.RES.0000171756.13554.49","article-title":"Neuropilin-1 regulates vascular endothelial growth factor-mediated endothelial permeability","volume":"96","author":"Becker","year":"2005","journal-title":"Circ Res"},{"key":"10.1016\/j.jhepr.2026.101731_bib21","doi-asserted-by":"crossref","first-page":"1336","DOI":"10.1038\/s41467-019-09296-6","article-title":"iRGD synergizes with PD-1 knockout immunotherapy by enhancing lymphocyte infiltration in gastric cancer","volume":"10","author":"Ding","year":"2019","journal-title":"Nat Commun"},{"key":"10.1016\/j.jhepr.2026.101731_bib22","article-title":"Glycoengineering-based anti-PD-1-iRGD peptide conjugate boosts antitumor efficacy through T cell engagement","volume":"5","author":"Pan","year":"2024","journal-title":"Cell Rep Med"},{"key":"10.1016\/j.jhepr.2026.101731_bib23","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-024-64610-7","article-title":"Targeting vascular disrupting agent-treated tumor microenvironment with tissue-penetrating nanotherapy","volume":"14","author":"Sidorenko","year":"2024","journal-title":"Sci Rep"},{"key":"10.1016\/j.jhepr.2026.101731_bib24","doi-asserted-by":"crossref","first-page":"5232","DOI":"10.1038\/srep05232","article-title":"Quantity and accessibility for specific targeting of receptors in tumours","volume":"4","author":"Hussain","year":"2014","journal-title":"Sci Rep"},{"key":"10.1016\/j.jhepr.2026.101731_bib25","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1016\/S2468-1253(22)00167-4","article-title":"Dual \u03b1V-integrin and neuropilin-1 targeting peptide CEND-1 plus nab-paclitaxel and gemcitabine for the treatment of metastatic pancreatic ductal adenocarcinoma: a first-in-human, open-label, multicentre, phase 1 study","volume":"7","author":"Dean","year":"2022","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1016\/j.jhepr.2026.101731_bib26","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.jconrel.2015.06.009","article-title":"A tumor-penetrating peptide enhances circulation-independent targeting of peritoneal carcinomatosis","volume":"212","author":"Sugahara","year":"2015","journal-title":"J Control Release"},{"key":"10.1016\/j.jhepr.2026.101731_bib27","first-page":"1719","article-title":"Transgenic mouse model for synergistic effects of nuclear oncogenes and growth factors in tumorigenesis: interaction of c-myc and transforming growth factor alpha in hepatic oncogenesis","volume":"53","author":"Murakami","year":"1993","journal-title":"Cancer Res"},{"key":"10.1016\/j.jhepr.2026.101731_bib28","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1596\/neo.111366","article-title":"Reduced efficacy of the Plk1 inhibitor BI 2536 on the progression of hepatocellular carcinoma due to low intratumoral drug levels","volume":"14","author":"Haupenthal","year":"2012","journal-title":"Neoplasia"},{"key":"10.1016\/j.jhepr.2026.101731_bib29","doi-asserted-by":"crossref","first-page":"105178","DOI":"10.1016\/j.ebiom.2024.105178","article-title":"Tumour-specific activation of a tumour-blood transport improves the diagnostic accuracy of blood tumour markers in mice","volume":"105","author":"Schmithals","year":"2024","journal-title":"EBioMedicine"},{"key":"10.1016\/j.jhepr.2026.101731_bib30","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.jhepr.2026.101731_bib31","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1186\/s12885-019-5907-7","article-title":"The design, analysis and application of mouse clinical trials in oncology drug development","volume":"19","author":"Guo","year":"2019","journal-title":"BMC Cancer"},{"key":"10.1016\/j.jhepr.2026.101731_bib32","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1053\/j.gastro.2008.09.014","article-title":"Incidence of hepatocellular carcinoma and associated risk factors in hepatitis C-related advanced liver disease","volume":"136","author":"Lok","year":"2009","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhepr.2026.101731_bib33","doi-asserted-by":"crossref","DOI":"10.1038\/nrdp.2016.18","article-title":"Hepatocellular carcinoma","volume":"2","author":"Llovet","year":"2016","journal-title":"Nat Rev Dis Primers"},{"key":"10.1016\/j.jhepr.2026.101731_bib34","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1038\/s41575-018-0033-6","article-title":"Mouse models of hepatocellular carcinoma: an overview and highlights for immunotherapy research","volume":"15","author":"Brown","year":"2018","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"10.1016\/j.jhepr.2026.101731_bib35","doi-asserted-by":"crossref","first-page":"980","DOI":"10.1016\/j.jhep.2008.12.033","article-title":"Increased intratumoral IL-17-producing cells correlate with poor survival in hepatocellular carcinoma patients","volume":"50","author":"Zhang","year":"2009","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhepr.2026.101731_bib36","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2020-000967","article-title":"Neuropilin-1: a checkpoint target with unique implications for cancer immunology and immunotherapy","volume":"8","author":"Chuckran","year":"2020","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.jhepr.2026.101731_bib37","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1038\/s41568-021-00339-z","article-title":"Antigen presentation in cancer: insights into tumour immunogenicity and immune evasion","volume":"21","author":"Jhunjhunwala","year":"2021","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.jhepr.2026.101731_bib38","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1038\/s41586-020-2229-5","article-title":"Autophagy promotes immune evasion of pancreatic cancer by degrading MHC-I","volume":"581","author":"Yamamoto","year":"2020","journal-title":"Nature"},{"key":"10.1016\/j.jhepr.2026.101731_bib39","doi-asserted-by":"crossref","first-page":"1965","DOI":"10.1136\/gutjnl-2020-322196","article-title":"High-affinity neoantigens correlate with better prognosis and trigger potent antihepatocellular carcinoma (HCC) activity by activating CD39+CD8+ T cells","volume":"70","author":"Liu","year":"2021","journal-title":"Gut"},{"key":"10.1016\/j.jhepr.2026.101731_bib40","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1038\/s41586-022-05400-x","article-title":"Liver tumour immune microenvironment subtypes and neutrophil heterogeneity","volume":"612","author":"Xue","year":"2022","journal-title":"Nature"},{"key":"10.1016\/j.jhepr.2026.101731_bib41","doi-asserted-by":"crossref","first-page":"1853","DOI":"10.1242\/jcs.111.13.1853","article-title":"Vascular endothelial growth factor induces VE-cadherin tyrosine phosphorylation in endothelial cells","volume":"111","author":"Esser","year":"1998","journal-title":"J Cell Sci"},{"key":"10.1016\/j.jhepr.2026.101731_bib42","doi-asserted-by":"crossref","DOI":"10.1126\/scisignal.aad3812","article-title":"Neuropilin-1 mediates vascular permeability independently of vascular endothelial growth factor receptor-2 activation","volume":"9","author":"Roth","year":"2016","journal-title":"Sci Signal"},{"key":"10.1016\/j.jhepr.2026.101731_bib43","doi-asserted-by":"crossref","DOI":"10.3390\/ijms24065700","article-title":"Assessment of the pharmacokinetics, disposition, and duration of action of the tumour-targeting peptide CEND-1","volume":"24","author":"J\u00e4rvel\u00e4inen","year":"2023","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.jhepr.2026.101731_bib44","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.1016\/j.jhep.2024.12.016","article-title":"Single-cell RNA sequencing-derived signatures define response patterns to atezolizumab + bevacizumab in advanced hepatocellular carcinoma","volume":"82","author":"Cappuyns","year":"2025","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhepr.2026.101731_bib45","first-page":"4","article-title":"Immunotherapy for hepatocellular carcinoma","author":"Guan","year":"2025","journal-title":"Clin Cancer Bull"},{"key":"10.1016\/j.jhepr.2026.101731_bib46","doi-asserted-by":"crossref","first-page":"3260","DOI":"10.1038\/s41598-019-40078-8","article-title":"Inflammatory cytokines and change of Th1\/Th2 balance as prognostic indicators for hepatocellular carcinoma in patients treated with transarterial chemoembolization","volume":"9","author":"Lee","year":"2019","journal-title":"Sci Rep"},{"key":"10.1016\/j.jhepr.2026.101731_bib47","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/j.immuni.2009.10.011","article-title":"CD44 regulates survival and memory development in Th1 cells","volume":"32","author":"Baaten","year":"2010","journal-title":"Immunity"},{"key":"10.1016\/j.jhepr.2026.101731_bib48","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1016\/j.ccr.2013.11.007","article-title":"Impeding macrophage entry into hypoxic tumor areas by Sema3A\/Nrp1 signaling blockade inhibits angiogenesis and restores antitumor immunity","volume":"24","author":"Casazza","year":"2013","journal-title":"Cancer Cell"},{"key":"10.1016\/j.jhepr.2026.101731_bib49","article-title":"Tumor-resident regulatory T cells in pancreatic cancer express the \u03b1v\u03b25 integrin as a targetable activation marker","author":"Suzuki","year":"2023","journal-title":"bioRxiv"},{"key":"10.1016\/j.jhepr.2026.101731_bib50","doi-asserted-by":"crossref","first-page":"1140","DOI":"10.3390\/cancers16071440","article-title":"Immune-related adverse events due to cancer immunotherapy: immune mechanisms and clinical manifestations","volume":"16","author":"Casagrande","year":"2024","journal-title":"Cancers"},{"key":"10.1016\/j.jhepr.2026.101731_bib51","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1038\/nrc2748","article-title":"Integrins in cancer: biological implications and therapeutic opportunities","volume":"10","author":"Desgrosellier","year":"2010","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.jhepr.2026.101731_bib52","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1053\/jhep.2002.34611","article-title":"Expression, regulation, and function of alpha V integrins in hepatocellular carcinoma: an in vivo and in vitro study","volume":"36","author":"Nejjari","year":"2002","journal-title":"Hepatology"},{"key":"10.1016\/j.jhepr.2026.101731_bib53","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1016\/j.jhep.2011.01.033","article-title":"Neuropilin-1 is upregulated in hepatocellular carcinoma and contributes to tumour growth and vascular remodelling","volume":"55","author":"Berg\u00e9","year":"2011","journal-title":"J Hepatol"}],"container-title":["JHEP Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2589555926000017?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2589555926000017?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,16]],"date-time":"2026-05-16T04:09:23Z","timestamp":1778904563000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2589555926000017"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3]]},"references-count":53,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,3]]}},"alternative-id":["S2589555926000017"],"URL":"https:\/\/doi.org\/10.1016\/j.jhepr.2026.101731","relation":{},"ISSN":["2589-5559"],"issn-type":[{"value":"2589-5559","type":"print"}],"subject":[],"published":{"date-parts":[[2026,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Co-administered internalizing RGD peptide boosts anti-PD-L1 therapy in hepatocellular carcinoma","name":"articletitle","label":"Article Title"},{"value":"JHEP Reports","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jhepr.2026.101731","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier B.V. on behalf of European Association for the Study of the Liver (EASL).","name":"copyright","label":"Copyright"}],"article-number":"101731"}}